Decision frees up resources for high-growth areas amid declining market share.
Getinge has announced plans to phase out its surgical perfusion business, citing declining market share and eroding margins over the past decade. The move allows the company to prioritize extracorporeal life support (ECLS) and transplant care, particularly following its $477 million acquisition of Paragonix Technologies.
Key Takeaways:
Surgical perfusion sales in 2024: SEK 450M ($42.6M), just 1.3% of Getinge’s total revenue.
Strategic shift: Resources reallocated to ECMO and organ transplant solutions.
Employee impact: Final restructuring decision pending labor negotiations.
Market impact: Competitor LivaNova expected to benefit, gaining additional market share.
CEO Mattias Vadsten emphasized the necessity of the transition:
“We are proud of our legacy in surgical perfusion, but we must focus on areas with higher growth potential and profitability.”
With Getinge’s exit, the surgical perfusion market faces a major shift, opening opportunities for competitors like LivaNova and Terumo.
Follow MEDWIRE.AI for the latest in medtech business strategy and market shifts.
